Core B evaluates and follows all participants entered into the studies of the program project. It uses an established clinical and psychometric protocol at entry and annually thereafter to obtain clinical, neurological, and behavioral data to carefully characterize each participant in support of each of the 3 Projects of this Program Project Grant (PPG).
Specific Aims of Core B are: 1. Maintain the current active cohort (n=225) of participants, carefully characterized as to the presence or absence of symptomatic AD, to support longitudinal studies of the clinical, cognitive, behavioral and biomedical correlates of symptomatic Alzheimer's disease (AD) in comparison with normal aging, and to mark the transition of cognitively normal participants with preclinical AD to cognitive impairment. 2. Annually enroll and assess 35 new participants (CDR 0=23;CDR 0.5/AD =12) each year who are age e 65 to replenish the Core's cohort to maintain a sufficient sample size (n~250) to support the aims of the PPG and to supply study participants and their data (and DNA to Project 3) to individual Projects: 3. Follow all participants with annual assessments and provide diagnostic and clinical and cognitive data to all Cores and Projects, working closely with Core C: Biostatistics and Core A: Administration to coordinate data acquisition and management to integrate the Core's activities with the scientific goals of the Program Project. In addition to HASD's traditional diagnostic methods, in this application HASD participants will (in accordance with the criteria established by the Alzheimer Disease Neuroimaging Initiative-2) also be classified as significant memory concern, early and late mild cognitive impairment (MCI). 4. Support Core D: Neuropathology through our voluntary autopsy consent program. 5. Support Core E: Imaging and all Projects by referring: a. all HASD participants for MRI and PET amyloid imaging session at baseline and every 3 years thereafter;b. provide Project 1 (Indicators of transition to symptomatic AD) clinical characterizations and data from cognitive measures of all participants;c. refer to Project 2 (Sleep: potential prognostic and theranostic marker for preclinical AD) all participants for sleep and cerebrospinal fluid studies;d. Collect blood from all newly enrolled Core participants for Project 3 (Identification of genetic variants associated with the progression of AD) for their GWAS and variant characterization.
Core B: Clinical Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.
|Day, Gregory S; Musiek, Erik S; Morris, John C (2018) Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis Assoc Disord 32:291-297|
|Aschenbrenner, Andrew J; Gordon, Brian A; Benzinger, Tammie L S et al. (2018) Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91:e859-e866|
|Villeneuve, Sylvia; Vogel, Jacob W; Gonneaud, Julie et al. (2018) Proximity to Parental Symptom Onset and Amyloid-? Burden in Sporadic Alzheimer Disease. JAMA Neurol 75:608-619|
|Karch, Celeste M; Hernández, Damián; Wang, Jen-Chyong et al. (2018) Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. Alzheimers Res Ther 10:69|
|Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 97:1284-1298.e7|
|Day, Gregory S; Gordon, Brian A; Perrin, Richard J et al. (2018) In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 90:e896-e906|
|Vardarajan, Badri N; Barral, Sandra; Jaworski, James et al. (2018) Whole genome sequencing of Caribbean Hispanic families with late-onset Alzheimer's disease. Ann Clin Transl Neurol 5:406-417|
|Lewczuk, Piotr; Riederer, Peter; O'Bryant, Sid E et al. (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 19:244-328|
|Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558|
|Joseph-Mathurin, Nelly; Su, Yi; Blazey, Tyler M et al. (2018) Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimers Dement (Amst) 10:669-677|
Showing the most recent 10 out of 911 publications